Evidence map›Paper›PMID 41278811›Full record

ArticlebioRxiv : the preprint server for biology2025

Stabilized Full-Length Measles Fusion Protein Elicits Potent Immunity and Protection In Vivo.

Dawid S Zyla, Gillian Zipursky, Roberta Della Marca, Davide Lacarbonara, Gele Niemeyer, Weiwei Peng, Camilla Predella, Kyle Stearns, Cameron Leedale, Jonathan Miller and 17 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Dawid S ZylaCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.ORCID 0000-0001-8471-469X
Gillian ZipurskyCenter for Host-Pathogen Interaction, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Roberta Della MarcaCenter for Host-Pathogen Interaction, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Davide LacarbonaraCenter for Host-Pathogen Interaction, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Gele NiemeyerCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Weiwei PengBiomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH, Utrecht, The Netherlands.
Camilla PredellaDepartment of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Kyle StearnsCenter for Host-Pathogen Interaction, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Cameron LeedaleDepartment of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA.
Jonathan MillerDepartment of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA.
Daniel TayDepartment of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Jonathan KaoCenter for Host-Pathogen Interaction, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Marissa AccianiCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Laura Di ClementeCenter for Host-Pathogen Interaction, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Anirban DasCenter for Host-Pathogen Interaction, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Diptiben ParekhCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Ruben Diaz AvalosCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Gael McGillDigizyme Inc., Brookline, MA, USA.
N Valerio DorrelloDepartment of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Kathryn M HastieCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Christopher A AlabiRobert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY 14853, USA.
Joost SnijderBiomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH, Utrecht, The Netherlands.
Anne MosconaCenter for Host-Pathogen Interaction, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Alexander L GreningerDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.ORCID 0000-0002-7443-0527
Stefan NiewieskDepartment of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA.ORCID 0000-0003-4487-073X
Erica Ollmann SaphireCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.ORCID 0000-0002-1206-7451
Matteo PorottoCenter for Host-Pathogen Interaction, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.ORCID 0000-0003-3866-9220

Funding

Clinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0M
Vaccines and Therapeutic Antibodies to Respiro, Rubula, Peribunya and Phenuiviridae (R2P2)-ReVAMPPU19AI181984 · NIAID · WASHINGTON UNIVERSITY · PI MOSCONA, ANNE, RAPPUOLI, RINO · 2024 to 2024
$44.1M
Mechanistic Virology CoreU19AI109762 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SAPHIRE, ERICA OLLMANN · 2014 to 2018
$29.6M
Design of fusion inhibitors to block measles host-to-host infectionR01AI176833 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Matteo Porotto · 2023 to 2026
$2.8M
Mechanisms of measles virus CNS adaptationR01NS091263 · NINDS · WEILL MEDICAL COLL OF CORNELL UNIV · PI POROTTO, MATTEO · 2015 to 2019
$1.9M
Development of therapeutic fusion inhibitor peptides for Measles encephalitisR01NS105699 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI POROTTO, MATTEO · 2018 to 2022
$1.8M
Thermostable measles fusion glycoprotein as a new vaccine strategyR56AI183536 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI POROTTO, MATTEO, SAPHIRE, ERICA OLLMANN · 2024 to 2024
$884k
Thermostable measles fusion glycoprotein as a new vaccine strategyR01AI190902 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Matteo Porotto, Erica Ollmann Saphire · 2026 to 2026
$883k
What is the human antibody response to measles virus vaccination?R21AI180456 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SAPHIRE, ERICA OLLMANN · 2024 to 2025
$496k
NCATS NIH HHS UL1 TR001873NIAID NIH HHS R01 AI176833NIAID NIH HHS R01 AI190902NIAID NIH HHS R21 AI180456NIAID NIH HHS R56 AI183536NIAID NIH HHS U19 AI109762NIAID NIH HHS U19 AI181984NINDS NIH HHS R01 NS091263NINDS NIH HHS R01 NS105699
6 · The paper itself

Abstract

Measles virus (MeV) is a highly contagious pathogen that causes significant morbidity and mortality in populations with low vaccination coverage. Infection typically leads to immune amnesia and, in rare cases, fatal neurological disease. While current live-attenuated vaccines are highly effective, they primarily elicit neutralizing antibodies against the hemagglutinin (H) glycoprotein, with a less robust response to the fusion (F) protein, a key protein for viral entry. To improve the immunogenicity of the F protein, we designed and characterized stabilized, prefusion MeV F protein antigens. We engineered both soluble ectodomains (F

Identifiers

PMID41278811
PMCPMC12632350

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.